 Home > Active Ingredient News > Antitumor Therapy > J Thorac Oncol: Efficacy of dabrafenib + trametinib in the treatment of metastatic BRAF V600E mutant non-small cell lung cancer: 5-year survival update

J Thorac Oncol: Efficacy of dabrafenib + trametinib in the treatment of metastatic BRAF V600E mutant non-small cell lung cancer: 5-year survival update

 Last Update: 2021-09-18
 Source: Internet
 Author: User

Tags

toner dry skin

cell time cellular

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In a multi-center, multi-cohort, non-randomized, open-label phase II study (NCT01336634), the ORR of patients receiving dabrafenib monotherapy (cohort A) was 33% (95% CI, 23%) -45%), the PFS is 5.

The primary endpoint is the overall response rate (ORR) assessed by the investigator based on the efficacy evaluation criteria for solid tumors version 1.

Cohort B eventually enrolled 57 patients, and cohort C enrolled 36 patients

At the time of data truncation, the median follow-up time of cohort B (57 cases) and cohort C (36 cases) were 16.

ORR of queue B

The DOR of patients in cohort B and cohort C were 9.

DoR

The median PFS (95% CI) of patients in cohort B and cohort C was 10.

PFS

The most common AEs (any grade) that occurred in ≥30% of patients were fever (56%), nausea (51%), vomiting (41%), dry skin (39%), peripheral edema (38%), Diarrhea (37%), decreased appetite (33%) and cough (31%)
.
The most common grade ≥3 adverse reactions that occurred in ≥5% of patients were hypertension, hyponatremia, neutropenia, fever, dyspnea, anemia, and elevated alanine aminotransferase
.

In summary, the study shows that dabrafenib + trametinib has sustained clinical benefits in the treatment of metastatic BRAF V600E mutant non-small cell lung cancer, and its safety is controllable, regardless of the previous treatment
.
This study shows that dabrafenib + trametinib has sustained clinical benefit in the treatment of metastatic BRAF V600E mutant non-small cell lung cancer, and its safety is controllable, regardless of the previous treatment
.
This study shows that dabrafenib + trametinib has sustained clinical benefit in the treatment of metastatic BRAF V600E mutant non-small cell lung cancer, and its safety is controllable, regardless of the previous treatment
.

Original source:

Planchard D, Besse B, Groen HJM, et al.
Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer: Updated 5-year survival rates and genomic analysis.
J Thorac Oncol.
2021 Aug 26:S1556-0864(21)02403-5.
doi: 10.
1016/j.
jtho.
2021.
08.
011.
Epub ahead of print.
PMID: 34455067.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.